Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ocrelizumab biosimilar by Celltrion for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Ocrelizumab biosimilar is under clinical development by Celltrion and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According...